Pharmeasy acquires a 66.1% stake in Thyrocare for INR 4,546cr


When 32-year-old Siddharth Shah, Co-founder & CEO of API Holdings, encountered 62 years old, diagnostic services veteran Dr. A Velumani, Chairman of Thyrocare in monsoon saturated Lonavala over masala tea at the Thyrocare Chairman’s house, and a breakthrough deal had struck in highest time.

The parent co. of digital Healthcare Brand, (PharmEasy), API Holdings Ltd (API), initiated by Dharmil Sheth, Dhaval Shah, Harsh Parekh, Hardik Dedhia, and Siddharth Shah, declared the passing of conclusive credentials to obtain a 66.1% stake in Thyrocare Technologies Ltd (Thyrocare) from Dr. A Velumani and associates for INR 1,300 per share accumulating to INR 4,546 CRS. The deal is topic to controlling and other relevant customary endorsements. Docon Technologies Pvt Ltd, a 100% subordinate of API, will be the acquirer and shall make an open offer for an extra 26% stake.

Dr. A Velumani will be distinctly obtaining a marginal non-controlling stake, of fewer than 5% in API as part of a succession of equity investments by present and new depositors of API. PharmEasy is India’s #1 online pharmacy and diagnostics brand, RetailIO – the country’s prime B2B pharma bazaar & vendor, and DocOn – a foremost consultation and EMR podium. The establishment has a devoted base of 12mn+ consumers, a network of 6,000+ digital consultation clinics, and 90,000+ associate sellers around the nation. It presently assists over 1mn patients for their pharmacy & diagnostics requirements, ways 300k+ consultations and distributes over 1mn digital prescriptions on a monthly source.

Thyrocare is the country’s #1 diagnostics solution distributor by capacity with over 110mn tests completed yearly. It is the principal B2B performer in the diagnostics area and has a system of 3,330+ collection centers around 2,000+ towns in India. Thyrocare functions as a multi-lab model with 1 mega central dispensation lab, 2 zonal processing labs, and 13 regional processing labs around the nation. Thyrocare operates with industry-foremost gross limits, and its lean cost structures brands it one of the utmost resourcefully run procedures in the diagnostics area. The association between PharmEasy and Thyrocare is exceptional and transformative for the Indian healthcare segment, customers, and the complete healthcare environment. The working together of both, country’s principal digital health podium and one of the major, gainful diagnostics key providers (by volume) will redesign and quicken the distribution of first-class diagnostic and OPD services crossways the complete continuum of patient care to nearly 800mn Indians.

Follow and connect with us on Facebook, LinkedIn & Twitter


Please enter your comment!
Please enter your name here